Annual Cash & Cash Equivalents
$143.99 M
+$35.96 M+33.28%
December 31, 2023
Summary
- As of February 7, 2025, ADAP annual cash & cash equivalents is $143.99 million, with the most recent change of +$35.96 million (+33.28%) on December 31, 2023.
- During the last 3 years, ADAP annual cash & cash equivalents has risen by +$87.11 million (+153.14%).
- ADAP annual cash & cash equivalents is now -37.13% below its all-time high of $229.05 million, reached on June 30, 2015.
Performance
ADAP Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$116.74 M
-$95.07 M-44.88%
September 30, 2024
Summary
- As of February 7, 2025, ADAP quarterly cash and cash equivalents is $116.74 million, with the most recent change of -$95.07 million (-44.88%) on September 30, 2024.
- Over the past year, ADAP quarterly cash and cash equivalents has dropped by -$23.93 million (-17.01%).
- ADAP quarterly cash and cash equivalents is now -46.22% below its all-time high of $217.08 million, reached on September 30, 2015.
Performance
ADAP Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ADAP Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +33.3% | -17.0% |
| 3 y3 years | +153.1% | +172.0% |
| 5 y5 years | +110.6% | +196.2% |
ADAP Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -4.0% | +33.3% | -44.9% | +51.7% |
| 5 y | 5-year | -4.0% | +185.6% | -44.9% | +260.0% |
| alltime | all time | -37.1% | >+9999.0% | -46.2% | +260.0% |
Adaptimmune Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $116.74 M(-44.9%) |
| Jun 2024 | - | $211.81 M(+50.6%) |
| Mar 2024 | - | $140.67 M(-2.3%) |
| Dec 2023 | $143.99 M(+33.3%) | $143.99 M(+59.9%) |
| Sep 2023 | - | $90.06 M(+17.0%) |
| Jun 2023 | - | $76.97 M(-35.8%) |
| Mar 2023 | - | $119.87 M(+11.0%) |
| Dec 2022 | $108.03 M(-28.0%) | $108.03 M(+36.7%) |
| Sep 2022 | - | $79.00 M(-19.2%) |
| Jun 2022 | - | $97.81 M(+9.2%) |
| Mar 2022 | - | $89.54 M(-40.3%) |
| Dec 2021 | $149.95 M(+163.6%) | $149.95 M(+249.4%) |
| Sep 2021 | - | $42.92 M(-14.9%) |
| Jun 2021 | - | $50.45 M(+55.6%) |
| Mar 2021 | - | $32.43 M(-43.0%) |
| Dec 2020 | $56.88 M(+12.8%) | $56.88 M(-27.5%) |
| Sep 2020 | - | $78.47 M(-35.9%) |
| Jun 2020 | - | $122.36 M(+41.6%) |
| Mar 2020 | - | $86.43 M(+71.4%) |
| Dec 2019 | $50.41 M | $50.41 M(+27.9%) |
| Sep 2019 | - | $39.41 M(+14.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2019 | - | $34.57 M(-30.7%) |
| Mar 2019 | - | $49.92 M(-27.0%) |
| Dec 2018 | $68.38 M(-18.6%) | $68.38 M(-55.3%) |
| Sep 2018 | - | $153.08 M(+261.8%) |
| Jun 2018 | - | $42.31 M(-20.7%) |
| Mar 2018 | - | $53.38 M(-36.5%) |
| Dec 2017 | $84.04 M(-47.1%) | $84.04 M(-42.2%) |
| Sep 2017 | - | $145.33 M(+19.1%) |
| Jun 2017 | - | $122.00 M(-28.5%) |
| Mar 2017 | - | $170.56 M(+7.4%) |
| Dec 2016 | $158.78 M(-18.3%) | $158.78 M(+13.1%) |
| Sep 2016 | - | $140.44 M(-6.9%) |
| Jun 2016 | - | $150.89 M(-7.9%) |
| Mar 2016 | - | $163.77 M(-24.6%) |
| Dec 2015 | $194.26 M(-15.2%) | - |
| Sep 2015 | - | $217.08 M(+114.0%) |
| Jun 2015 | $229.05 M(+346.7%) | - |
| Dec 2014 | - | $101.43 M(+97.8%) |
| Jun 2014 | $51.27 M(>+9900.0%) | $51.27 M |
| Jun 2013 | $247.80 K(-91.8%) | - |
| Jun 2012 | $3.02 M | - |
FAQ
- What is Adaptimmune Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual cash & cash equivalents year-on-year change?
- What is Adaptimmune Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Adaptimmune Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ADAP is $143.99 M
What is the all time high annual cash & cash equivalents for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual cash & cash equivalents is $229.05 M
What is Adaptimmune Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ADAP annual cash & cash equivalents has changed by +$35.96 M (+33.28%)
What is Adaptimmune Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ADAP is $116.74 M
What is the all time high quarterly cash and cash equivalents for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly cash and cash equivalents is $217.08 M
What is Adaptimmune Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ADAP quarterly cash and cash equivalents has changed by -$23.93 M (-17.01%)